OSDD pipeline to define the current status formulate our progression patterns with an intention of focusing our resources onto advanced projects to accelerate delivery. As can be seen in the pipeline, the focus is on the earlier part of the discovery path and programs like LAMS and CDRI 830 have starting points that have huge potential to be taken further. The program will now focus on detailing the structure activity relationship (SAR), defining chemical structures of the compounds that are responsible for biological activity (MIC on M. tuberculosis). This is a challenging phase of the program as delineating the target of the thiophene series and building the SAR correlation between the enzyme inhibitors and biological activity in the LAMS program is necessary for processing these compounds. The portfolio highlights the different approaches like whole cell based and/or target based along with different lead generation approaches such as, random, focused, virtual, natural product screening, substrate analogues etc. towards generating novel starting points. OSDD would like to establish necessary support functions to progress projects in the pipeline. For example, chemistry outsourcing and in vivo evaluation. OSDD hopes to bring compounds at later stages of development into clinical trials, to help complete the experience to deliver new drugs for TB therapy.

OSDD has currently entered into agreement with Global TB Alliance for developing PA-824 in India, which will be taken into clinical trial in a three arm study to be conducted at LRS Institute of Tuberculosis andRespiratory Diseases. OSDD is also in discussion with various national and international organizations for the development of some clinical and pre-clinical candidates which includes both new drugs and repurposing drugs for treatment of TB.